PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells
Cells · 05.03.2026 · 15 (5) · 473
DOI: 10.3390/cells15050473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 05.03.2026. Verfasst von Yeongji Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Repu…. Hauptthemen laut MEDLINE: Osteosarcoma, Proto-Oncogene Proteins c-mdm2, Signal Transduction, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Evaluation Institute of Industrial Technology.
Abstract (Originalsprache)
Osteosarcoma, the most common malignant bone tumor in young individuals, often exhibits poor outcomes due to MDM2-mediated suppression of the p53 pathway. Whereas conventional MDM2 inhibitors block the p53–MDM2 interaction but frequently induce compensatory MDM2 upregulation, proteolysis-targeting chimeras (PROTACs) directly degrade MDM2 and bypass this limitation. Here, we investigated the anticancer efficacy of two MDM2-targeting PROTAC compounds, CL0144 and CL0174, in osteosarcoma models. In Saos-2 and U2OS cells, both PROTACs efficiently induced MDM2 degradation, leading to activation of p53 or p73 signaling, increased reactive oxygen species production, apoptotic cell death, and marked reductions in viability. PROTAC treatment also significantly suppressed proliferation, colony formation, sphere formation, migration, and invasion. In vivo, xenograft assays demonstrated robust tumor growth inhibition following PROTAC administration. Collectively, these findings demonstrate that MDM2-targeting PROTACs exert strong antitumor effects by degrading MDM2 and disrupting downstream oncogenic pathways, supporting their potential as a promising therapeutic strategy for osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea.
- Department of Orthopaedic Surgery, Nowon Eulji Medical Center, Eulji University, Seoul 01830, Republic of Korea.
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
- Department of Oral Microbiology and Immunology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 08826, Republic of Korea.
- TARS Scientific, Seoul 01717, Republic of Korea.
- Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University, 170, Juhwa-ro, Ilsangeo-gu, Goyang-si 10380, Republic of Korea.
ORCID-Profile: Yeongji Kim, Jin-Woo Kim, Hyunju An, Minsup Kim
Förderung
- National Research Foundation of Korea
- Korea Evaluation Institute of Industrial Technology
Zitieren
APA
Kim, Y., Kim, J. W., Choi, J., Kim, J., Park, S., Choi, W., An, H., Kim, J., Kim, M., Choi, S., Lim, J., Lee, H. I., & Lee, S. (2026). PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. Cells, 15(5), 473. https://doi.org/10.3390/cells15050473
Vancouver
Kim Y, Kim JW, Choi J, Kim J, Park S, Choi W, et al. PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. Cells. 2026;15(5):473. doi:10.3390/cells15050473
BibTeX
@article{Kim2026,
author = {Kim, Yeongji and Kim, Jin-Woo and Choi, Junwon and Kim, Jinhyeong and Park, Soyeon and Choi, Wonji and An, Hyunju and Kim, Jinman and Kim, Minsup and Choi, Sujin and Lim, Jinsu and Lee, Hyun Il and Lee, Soonchul},
title = {PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells},
journal = {Cells},
year = {2026},
volume = {15},
number = {5},
pages = {473},
doi = {10.3390/cells15050473}
}
EUVIMED